Andrew Hill Sees Lilly’s GLP-1 Cash Flow Funding Broader Pipeline
The fund says demand for Lilly’s diabetes and weight-loss therapies is generating cash for research, development and strategic acquisitions.
Key takeaways
- Andrew Hill Investment Fund said strong therapy demand is generating substantial cash flow for Lilly.
- The fund cited pipeline investments in oncology, neuroscience, immunology and emerging mental health treatments.
Andrew Hill Investment Fund said Eli Lilly’s strong demand for diabetes and weight-loss therapies is generating cash to support future growth. The fund outlined its view in a third-quarter 2026 investor letter.
The fund said Lilly can reinvest proceeds from those therapies in research, development and strategic acquisitions. It pointed to investments across oncology, neuroscience, immunology and emerging mental health treatments.
Andrew Hill described this cycle of commercial success funding future innovation as a “powerful” growth flywheel. The fund said it sees Lilly’s current GLP-1 position as a source of potential future medical breakthroughs.
This article was produced with the help of AI technology. Source: Yahoo Finance
